Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Shares Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company boosted its holdings in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 43.2% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,199 shares of the company’s stock after purchasing an additional 7,000 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Tenaya Therapeutics were worth $72,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Squarepoint Ops LLC grew its position in shares of Tenaya Therapeutics by 86.0% during the second quarter. Squarepoint Ops LLC now owns 120,704 shares of the company’s stock worth $374,000 after buying an additional 55,816 shares in the last quarter. Integral Health Asset Management LLC boosted its stake in Tenaya Therapeutics by 3.3% during the 2nd quarter. Integral Health Asset Management LLC now owns 2,325,000 shares of the company’s stock valued at $7,208,000 after acquiring an additional 75,000 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Tenaya Therapeutics by 144.1% during the 2nd quarter. Renaissance Technologies LLC now owns 157,460 shares of the company’s stock worth $488,000 after acquiring an additional 92,960 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Tenaya Therapeutics by 42.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 102,026 shares of the company’s stock worth $316,000 after purchasing an additional 30,446 shares during the last quarter. Finally, American Century Companies Inc. increased its position in shares of Tenaya Therapeutics by 27.7% in the 2nd quarter. American Century Companies Inc. now owns 102,114 shares of the company’s stock worth $317,000 after purchasing an additional 22,146 shares during the last quarter. 90.54% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Tenaya Therapeutics news, CEO Faraz Ali sold 9,748 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $2.89, for a total value of $28,171.72. Following the sale, the chief executive officer now directly owns 188,331 shares in the company, valued at approximately $544,276.59. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold a total of 19,539 shares of company stock worth $56,468 in the last three months. 32.76% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on TNYA shares. Leerink Partners reaffirmed an “outperform” rating on shares of Tenaya Therapeutics in a research report on Friday. Canaccord Genuity Group reaffirmed a “buy” rating and set a $16.00 target price on shares of Tenaya Therapeutics in a report on Friday. Piper Sandler reiterated an “overweight” rating on shares of Tenaya Therapeutics in a research report on Friday. Finally, HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Tenaya Therapeutics in a research report on Friday. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tenaya Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $15.25.

Tenaya Therapeutics Trading Down 5.1 %

TNYA opened at $2.04 on Monday. The company’s 50-day moving average price is $2.27 and its 200 day moving average price is $3.27. Tenaya Therapeutics, Inc. has a fifty-two week low of $1.61 and a fifty-two week high of $7.01.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06. Equities analysts expect that Tenaya Therapeutics, Inc. will post -1.52 EPS for the current fiscal year.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.